T
Tolerance Bio
Innovative therapies enhancing immune tolerance by restoring thymus function to combat immune-mediated diseases
About Tolerance Bio
Tolerance Bio is at the forefront of developing innovative therapies aimed at enhancing immune tolerance by restoring and preserving the function of the thymus, a critical organ in the immune system. The company targets immune-mediated diseases, which include cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies. These conditions represent significant unmet medical challenges due to abnormalities in immune tolerance. Tolerance Bio operates in the biotechnology sector, focusing on a multi-platform approach to manipulate thymus function, thereby addressing the root causes of these diseases. The business model involves pioneering novel therapeutics with the potential to rapidly advance and validate concepts in rare diseases, followed by proof of concept in broader indications. Revenue is generated through the development and commercialization of these therapeutics, targeting both niche and major markets. The company serves healthcare providers, researchers, and patients seeking advanced solutions for immune-related conditions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- Philadelphia, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 73.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Aug 2026 | $0 | — | NeolmmuneTech | ↗ |
| EARLY VC✓Equity / VC | Jun 2026 | $0 | — | BCI · Beyond Celiac | ↗ |
Growth signals
Latest recorded traffic for Tolerance Bio is 1.7K monthly website visits, up 13.3% over the last three months. Tolerance Bio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Columbus Venture Partners
Ben Franklin Technology Partners of Northeastern Pennsylvania
Criteria Bio Ventures
BioAdvance- PVPacific 8 Ventures
- SCSessa Capital
Series A3 investors entered at this stage
BCI
Beyond Celiac
NeolmmuneTech
Other known investors3 additional known investors
University of Colorado
University of Colorado Anschutz Medical Campus
University of Florida
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tolerance Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tolerance Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.